Home › Funds › Fund Evaluation Group, LLC › CATH

Fund Evaluation Group, LLC position in CATH

GLOBAL X FDS

Fund Evaluation Group, LLC reported holding 960,755 shares of CATH (GLOBAL X FDS) in its Q3 2026 13F filing — a position valued at US$87.1M, representing 2.06% of its reported portfolio and ranking #11 among its reported holdings. Fund Evaluation Group, LLC has disclosed CATH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)960.75K sh
Reported value held$87.12M
Portfolio Weight2.06%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Fund Evaluation Group, LLC's CATH position evolved

Fund Evaluation Group, LLC first disclosed a stake in CATH in Q3 2023 at 381,977 shares (US$20.0M). The position peaked in Q3 2026 at 960,755 shares, worth US$87.1M. Across 13 filings, Fund Evaluation Group, LLC increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 960,755 shares valued at US$87.1M — a reduction of -15,728 shares quarter over quarter.. Notable position changes include a 30% increase in Q1 2025 (shares rose 12% over the following quarter), a 54% increase in Q3 2025 (shares rose 1% over the following quarter), a 32% increase in Q2 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 381.98K $19.98M New
Q4 2023 380.70K $22.08M Hold
Q1 2024 387.02K $24.63M Add
Q2 2024 397.93K $26.02M Add
Q3 2024 298.49K $20.71M Reduce
Q4 2024 373.20K $26.44M Add
Q1 2025 486.37K $32.85M Add
Q2 2025 476.07K $35.92M Reduce
Q3 2025 733.24K $59.44M Add
Q4 2025 685.65K $56.38M Reduce
Q1 2026 738.46K $57.71M Add
Q2 2026 976.48K $86.42M Add
Q3 2026 960.75K $87.12M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CATH and 13F data

CATH (GLOBAL X FDS) is a company whose sector is not yet classified in our data. 30 other funds we track also report a position in CATH — the largest reported positions include CENTRAL TRUST Co (US$42.4M), BCM ADVISORS, LLC (US$19.6M), Choate Investment Advisors (US$19.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CATH

All CATH fund holders →

FAQ

How long has Fund Evaluation Group, LLC held CATH?

Fund Evaluation Group, LLC has disclosed CATH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Fund Evaluation Group, LLC's current position in CATH?

As of Q3 2026, Fund Evaluation Group, LLC holds 960.75K shares of CATH (GLOBAL X FDS), valued at $87.12M, representing 2.06% of its reported portfolio and ranking #11.

Has Fund Evaluation Group, LLC been buying or selling CATH?

In the latest 13F filing (Q3 2026), Fund Evaluation Group, LLC reduced its position in CATH. The position peaked in Q3 2026 at 960.75K shares.

Which other funds hold CATH?

Other major institutional holders of CATH include CENTRAL TRUST Co, BCM ADVISORS, LLC, Choate Investment Advisors, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.